Maybe you've noticed it yourself. Someone goes on Ozempic or Zepbound to lose weight, and a few months later they mention they've basically gone off alcohol. They're not really fancying a drink any more. It happens often enough that scientists started asking the obvious question: is the shot doing that? And if it is, could it help my mom, my dad, my brother, the person I'm actually worried about?

It's a hopeful thought, and I don't want to flatten it. But I also don't want to sell you something that isn't real yet. So let's go through what the evidence actually says, where it's strong, where it's thin, and what to do if someone you love is struggling right now.

The short answer

The science on GLP-1s and drinking is genuinely promising, and it's the strongest of any addiction. Two randomized trials and some very large real-world studies all point the same way: less craving, less heavy drinking. But it's early. The trials are small, they're short, and a lot of them studied people who also had obesity, so we can't be sure it works the same in everyone. And no regulator anywhere, the FDA included, has approved a GLP-1 to treat addiction. So the honest position is cautious hope, not a cure.

The alcohol evidence, plainly

Start with the gold standard, randomized controlled trials, where people are randomly given the drug or a placebo.

• A small trial (JAMA Psychiatry, 2025): 48 adults with alcohol use disorder, given low-dose semaglutide or placebo for 9 weeks (the people in it weren't actively seeking treatment). The semaglutide group drank less in lab tests and reported less craving. The effects were medium-to-large for a first trial. Interestingly, the smokers in it also cut down.
• A larger trial (The Lancet, 2026): 108 people with alcohol use disorder who also had obesity, given semaglutide or placebo alongside therapy for 26 weeks. Heavy drinking days roughly halved, a meaningful drop versus placebo (a difference of about 14 percentage points).

Then there's the real-world data, which is huge but weaker. A study of hundreds of thousands of patients in Nature Communications found people on semaglutide were around half as likely to be diagnosed with alcohol use disorder. A Swedish national-register study of nearly 228,000 people with alcohol use disorder found those on semaglutide or liraglutide had a lower risk of hospitalization, including alcohol-related admissions.

Why "weaker"? Because these are observational studies. They can show that two things go together, but not that the drug caused it. People prescribed these shots differ from people who aren't, in lots of ways that are hard to fully account for. And when researchers pooled the randomized trials, the average effect on consumption was smaller and not always statistically significant. So the picture is real and reproducible, but not yet settled.

"It represents, at present, the most robust and yet preliminary piece of evidence suggesting that these medications may indeed be useful for the care of people with alcohol use disorder."
Dr. Riccardo De Giorgi, University of Oxford, via the Science Media Centre

Why would a weight-loss drug touch drinking at all?

This is the bit that makes it click. GLP-1 receptors aren't only in your gut. They also sit in the parts of the brain that handle reward, the areas with names like the ventral tegmental area and the nucleus accumbens. That's the circuitry alcohol, nicotine and other drugs hijack to make you want more.

When a GLP-1 medicine switches those receptors on, it seems to turn down the dopamine "reward" hit. In plain terms, the drink delivers less of a kick, so the pull to have another one eases. In animal studies, putting a GLP-1 drug straight into those reward regions cut alcohol intake on its own, which suggests it's working on the brain's wanting system, not just on appetite. Most of the fine detail still comes from animals, so treat the mechanism as a strong hunch rather than a closed case.

What about smoking, opioids and other addictions?

Here the evidence thins out fast, and it cuts both ways.

• Smoking: mixed. A small trial of exenatide added to nicotine patches suggested higher quit rates, though it wasn't statistically conclusive. But the largest dedicated trial, of dulaglutide, found no improvement in actually quitting, only less weight gain. A semaglutide trial reduced nicotine craving but didn't cut cigarettes per day.
• Opioids: a large real-world study linked semaglutide to lower opioid-overdose risk in people with diabetes and opioid use disorder. Promising, but observational.
• Cocaine and stimulants: the one human trial found no effect on cocaine use, despite hopeful animal data.
• Gambling and other behavioral addictions: anecdotes only. No trials.

So alcohol is the front-runner by a distance. Everywhere else, it's early days or genuinely unclear.

The honest catch

I want to be straight about the limits, because false hope is its own kind of harm.

• The randomized trials are small and short. We don't know if the benefit lasts, or what happens to drinking when someone stops the drug.
• Most of the strong human data is in people who also had obesity. Many people with serious alcohol problems are underweight, not overweight, and we don't yet know if it works the same for them.
• It is not approved, anywhere, for this. Chasing a weight-loss shot as an alcohol treatment means going off-label for something unproven, instead of getting help that works now.

"It will be important to see if the effects of semaglutide are maintained over a longer time period, and, crucially, what happens when people stop taking the medication."
Professor Matt Field, University of Sheffield, via the Science Media Centre

If you're asking for a family member

If you came here because you're worried about your mom, your dad, someone you love, here's the kind thing to do with all this. Don't pin your hopes on the shot, and don't wait for the science to catch up. The proven help exists right now, and it works: a talk with a primary care doctor or an addiction specialist, counseling, and three medications the FDA has actually approved for alcohol use disorder (naltrexone, which comes as a daily pill or a monthly injection, acamprosate and disulfiram), used alongside that support.

If your person is also living with obesity and a clinician thinks a GLP-1 like Zepbound or Wegovy is right for their weight, and a happy side effect is less drinking, that's a conversation worth having with their prescriber. But it's the doctor's call, in context, not a reason to buy a shot from a sketchy online seller and hope.

FAQs

Can GLP-1s like Ozempic help someone stop drinking?

Possibly, but it's not proven and it's not approved for this. Early randomized trials and large real-world studies suggest semaglutide can reduce alcohol craving and heavy drinking, but the trials are small and short, and many studied people who also had obesity. No GLP-1 is approved anywhere to treat alcohol use disorder. It's a promising research area, not a treatment you can ask for yet.

Why would a weight-loss drug affect drinking?

GLP-1 receptors aren't only in the gut. They also sit in the brain's reward circuitry. Animal and early human studies suggest GLP-1 medicines turn down the dopamine reward signal that alcohol and other drugs trigger, which can lower craving.

Can I get a GLP-1 prescribed for alcohol use in the US?

No. In the US the FDA has cleared these drugs only for weight management and type 2 diabetes. Using one for alcohol or any addiction would be off-label and outside current guidance. The FDA-approved medications for alcohol use disorder are naltrexone (a pill or a monthly injection), acamprosate and disulfiram, used alongside counseling.

Do GLP-1s help with other addictions like smoking or opioids?

The signal is weaker and more mixed than for alcohol. Some studies suggest reduced nicotine craving and lower opioid-overdose risk, but a dedicated smoking trial found no improvement in quitting, and a small cocaine trial found no effect. It's early everywhere except alcohol, and even there it's not settled.

Related reading

• GLP-1 weight-loss drugs explained (Wegovy, Ozempic, Zepbound)
• The Wegovy pill: oral semaglutide, explained

Sources

• Hendershot et al. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder (RCT). JAMA Psychiatry 2025. pmc.ncbi.nlm.nih.gov
• Klausen et al. Semaglutide for alcohol use disorder with obesity (RCT). The Lancet 2026. pubmed.ncbi.nlm.nih.gov
• Wang et al. Associations of semaglutide with incidence and recurrence of alcohol use disorder. Nature Communications 2024. pmc.ncbi.nlm.nih.gov
• Lähteenvuo et al. Repurposing Semaglutide and Liraglutide for Alcohol Use Disorder. JAMA Psychiatry 2024. jamanetwork.com
• Moreira Alves et al. Mechanisms of GLP-1 in Modulating Craving and Addiction. Medical Sciences 2025. pmc.ncbi.nlm.nih.gov
• Systematic review, GLP-1 receptor agonists in substance use disorders. Frontiers in Pharmacology 2026. frontiersin.org
• NIAAA (National Institute on Alcohol Abuse and Alcoholism), Medications for the treatment of alcohol use disorder. niaaa.nih.gov
• SAMHSA, National Helpline and treatment referral. samhsa.gov